Stock Analysis

Asian Stocks Estimated To Be Trading Below Intrinsic Value In July 2025

KOSE:A000100
Source: Shutterstock

In recent weeks, Asian markets have shown mixed performance, with China's stock indices experiencing modest gains while Japan's indices faced declines amid trade negotiation uncertainties. Amid these fluctuations, investors are increasingly looking for opportunities in stocks that may be trading below their intrinsic value, as undervalued stocks can present potential growth prospects when the broader market conditions stabilize.

Advertisement

Top 10 Undervalued Stocks Based On Cash Flows In Asia

NameCurrent PriceFair Value (Est)Discount (Est)
Zhejiang Leapmotor Technology (SEHK:9863)HK$57.90HK$115.3249.8%
Taiyo Yuden (TSE:6976)¥2575.00¥5105.3949.6%
Ningbo Sanxing Medical ElectricLtd (SHSE:601567)CN¥23.15CN¥46.0449.7%
JRCLtd (TSE:6224)¥1161.00¥2302.9949.6%
Evergreen Aviation Technologies (TWSE:2645)NT$99.00NT$195.5349.4%
Darbond Technology (SHSE:688035)CN¥39.65CN¥78.3449.4%
cottaLTD (TSE:3359)¥427.00¥853.1750%
Astroscale Holdings (TSE:186A)¥673.00¥1345.9550%
APAC Realty (SGX:CLN)SGD0.48SGD0.9549.2%
Accton Technology (TWSE:2345)NT$813.00NT$1600.1949.2%

Click here to see the full list of 270 stocks from our Undervalued Asian Stocks Based On Cash Flows screener.

Here we highlight a subset of our preferred stocks from the screener.

Yuhan (KOSE:A000100)

Overview: Yuhan Corporation is involved in the manufacturing and sale of prescription drugs, over-the-counter drugs, veterinary drugs, and household goods both in South Korea and internationally, with a market cap of ₩8.38 trillion.

Operations: The company's revenue segments include biotechnology startups, contributing ₩2.11 billion.

Estimated Discount To Fair Value: 22.1%

Yuhan Corporation is trading at ₩112,100, significantly below its estimated fair value of ₩143,953.77. The company has announced a share repurchase program to enhance shareholder value, which could positively impact stock valuation. Despite a decline in profit margins from 6.8% to 3.1%, Yuhan's earnings are expected to grow substantially at 44.1% annually over the next three years, outpacing the Korean market's growth rate of 20.9%.

KOSE:A000100 Discounted Cash Flow as at Jul 2025
KOSE:A000100 Discounted Cash Flow as at Jul 2025

Beijing Zhong Ke San Huan High-Tech (SZSE:000970)

Overview: Beijing Zhong Ke San Huan High-Tech Co., Ltd. operates in the high-tech sector with a focus on advanced material technologies and has a market cap of CN¥14.79 billion.

Operations: Beijing Zhong Ke San Huan High-Tech Co., Ltd. generates its revenue from advanced material technologies, contributing to its market presence in the high-tech sector.

Estimated Discount To Fair Value: 39.7%

Beijing Zhong Ke San Huan High-Tech is trading at CN¥12.29, significantly below its estimated fair value of CN¥20.38, indicating it may be undervalued based on cash flows. Despite a recent dividend decrease, the company reported a net income of CN¥13.49 million for Q1 2025, rebounding from a loss last year. Earnings are projected to grow substantially at 43.92% annually over the next three years, outpacing the Chinese market's growth rate of 23.4%.

SZSE:000970 Discounted Cash Flow as at Jul 2025
SZSE:000970 Discounted Cash Flow as at Jul 2025

Pansoft (SZSE:300996)

Overview: Pansoft Company Limited offers management information solutions and IT integrated services for large enterprises in China, with a market cap of CN¥5.34 billion.

Operations: Pansoft generates revenue through its management information solutions and IT integrated services for large enterprises in China.

Estimated Discount To Fair Value: 31.8%

Pansoft Company Limited is currently trading at CN¥19.08, below its estimated fair value of CN¥27.98, suggesting it could be undervalued based on cash flows. Despite a challenging first quarter with a net loss of CNY 13.95 million and volatile share price, earnings are forecast to grow significantly at 32.2% annually over the next three years, surpassing market expectations. However, investors should note its unstable dividend history amidst recent changes in company bylaws and capital structure adjustments.

SZSE:300996 Discounted Cash Flow as at Jul 2025
SZSE:300996 Discounted Cash Flow as at Jul 2025

Next Steps

Contemplating Other Strategies?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

About KOSE:A000100

Yuhan

Manufactures and sells prescription drugs, over-the-counter drugs, veterinary drugs, and household goods in South Korea and internationally.

Reasonable growth potential with adequate balance sheet.

Advertisement